Lum BL - Search Results

1

A single dose mass balance study of the Hedgehog pathway inhibitor vismodegib (GDC-0449) in humans using accelerator mass spectrometry.

Graham RA, Lum BL, Morrison G, Chang I, Jorga K, Dean B, Shin YG, Yue Q, Mulder T, Malhi V, Xie M, Low JA, Hop CE. Graham RA, et al. Among authors: lum bl. Drug Metab Dispos. 2011 Aug;39(8):1460-7. doi: 10.1124/dmd.111.039339. Epub 2011 May 20. Drug Metab Dispos. 2011. PMID: 21602311 Clinical Trial.

2

Determination of GDC-0449, a small-molecule inhibitor of the Hedgehog signaling pathway, in human plasma by solid phase extraction-liquid chromatographic-tandem mass spectrometry.

Ding X, Chou B, Graham RA, Cheeti S, Percey S, Matassa LC, Reuschel SA, Meng M, Liu S, Voelker T, Lum BL, Rudewicz PJ, Hop CE. Ding X, et al. Among authors: lum bl. J Chromatogr B Analyt Technol Biomed Life Sci. 2010 Mar 15;878(9-10):785-90. doi: 10.1016/j.jchromb.2010.01.039. Epub 2010 Feb 1. J Chromatogr B Analyt Technol Biomed Life Sci. 2010. PMID: 20172765

3

Pharmacokinetics of hedgehog pathway inhibitor vismodegib (GDC-0449) in patients with locally advanced or metastatic solid tumors: the role of alpha-1-acid glycoprotein binding.

Graham RA, Lum BL, Cheeti S, Jin JY, Jorga K, Von Hoff DD, Rudin CM, Reddy JC, Low JA, Lorusso PM. Graham RA, et al. Among authors: lum bl. Clin Cancer Res. 2011 Apr 15;17(8):2512-20. doi: 10.1158/1078-0432.CCR-10-2736. Epub 2011 Feb 7. Clin Cancer Res. 2011. PMID: 21300760 Free PMC article. Clinical Trial.

4

Identification, characterization, and implications of species-dependent plasma protein binding for the oral Hedgehog pathway inhibitor vismodegib (GDC-0449).

Giannetti AM, Wong H, Dijkgraaf GJ, Dueber EC, Ortwine DF, Bravo BJ, Gould SE, Plise EG, Lum BL, Malhi V, Graham RA. Giannetti AM, et al. Among authors: lum bl. J Med Chem. 2011 Apr 28;54(8):2592-601. doi: 10.1021/jm1008924. Epub 2011 Mar 25. J Med Chem. 2011. PMID: 21438527

5

Single and multiple dose intravenous and oral pharmacokinetics of the hedgehog pathway inhibitor vismodegib in healthy female subjects.

Graham RA, Hop CE, Borin MT, Lum BL, Colburn D, Chang I, Shin YG, Malhi V, Low JA, Dresser MJ. Graham RA, et al. Among authors: lum bl. Br J Clin Pharmacol. 2012 Nov;74(5):788-96. doi: 10.1111/j.1365-2125.2012.04281.x. Br J Clin Pharmacol. 2012. PMID: 22458643 Free PMC article. Clinical Trial.

6

A survey of renal impairment pharmacokinetic studies for new oncology drug approvals in the USA from 2010 to early 2015: a focus on development strategies and future directions.

Xiao JJ, Chen JS, Lum BL, Graham RA. Xiao JJ, et al. Among authors: lum bl. Anticancer Drugs. 2017 Aug;28(7):677-701. doi: 10.1097/CAD.0000000000000513. Anticancer Drugs. 2017. PMID: 28542036 Free PMC article. Review.

7

Metabolism and excretion of erlotinib, a small molecule inhibitor of epidermal growth factor receptor tyrosine kinase, in healthy male volunteers.

Ling J, Johnson KA, Miao Z, Rakhit A, Pantze MP, Hamilton M, Lum BL, Prakash C. Ling J, et al. Among authors: lum bl. Drug Metab Dispos. 2006 Mar;34(3):420-6. doi: 10.1124/dmd.105.007765. Epub 2005 Dec 28. Drug Metab Dispos. 2006. PMID: 16381666

8

A survey of new oncology drug approvals in the USA from 2010 to 2015: a focus on optimal dose and related postmarketing activities.

Lu D, Lu T, Stroh M, Graham RA, Agarwal P, Musib L, Li CC, Lum BL, Joshi A. Lu D, et al. Among authors: lum bl. Cancer Chemother Pharmacol. 2016 Mar;77(3):459-76. doi: 10.1007/s00280-015-2931-4. Epub 2016 Jan 25. Cancer Chemother Pharmacol. 2016. PMID: 26811176 Free PMC article. Review.

9

Prevalence of acid-reducing agents (ARA) in cancer populations and ARA drug-drug interaction potential for molecular targeted agents in clinical development.

Smelick GS, Heffron TP, Chu L, Dean B, West DA, Duvall SL, Lum BL, Budha N, Holden SN, Benet LZ, Frymoyer A, Dresser MJ, Ware JA. Smelick GS, et al. Among authors: lum bl. Mol Pharm. 2013 Nov 4;10(11):4055-62. doi: 10.1021/mp400403s. Epub 2013 Oct 24. Mol Pharm. 2013. PMID: 24044612

10

Clinical pharmacokinetics of bevacizumab in patients with solid tumors.

Lu JF, Bruno R, Eppler S, Novotny W, Lum B, Gaudreault J. Lu JF, et al. Cancer Chemother Pharmacol. 2008 Oct;62(5):779-86. doi: 10.1007/s00280-007-0664-8. Epub 2008 Jan 19. Cancer Chemother Pharmacol. 2008. PMID: 18205003

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

113 results

Search Page

Filters